Clinical Trial Update: FT836 CAR T-cell Therapy in Combination With Daratumumab in Patients With Relapsed and/or Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating FT836 CAR T-cell therapy in combination with daratumumab for relapsed or refractory multiple myeloma; status: not yet recruiti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Daratumumab (daratumumab)
• FT836

Snippet

Sponsor: Medical College of Wisconsin | Conditions: Relapse Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Status: NOT_YET_RECRUITING